137 related articles for article (PubMed ID: 34237622)
1. Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
Zaraei SO; Sbenati RM; Alach NN; Anbar HS; El-Gamal R; Tarazi H; Shehata MK; Abdel-Maksoud MS; Oh CH; El-Gamal MI
Eur J Med Chem; 2021 Nov; 224():113674. PubMed ID: 34237622
[TBL] [Abstract][Full Text] [Related]
2. Structural optimization of imidazothiazole derivatives affords a new promising series as B-Raf V600E inhibitors; synthesis, in vitro assay and in silico screening.
Ammar UM; Abdel-Maksoud MS; Ali EMH; Mersal KI; Ho Yoo K; Oh CH
Bioorg Chem; 2020 Jul; 100():103967. PubMed ID: 32470760
[TBL] [Abstract][Full Text] [Related]
3. Modification of imidazothiazole derivatives gives promising activity in B-Raf kinase enzyme inhibition; synthesis, in vitro studies and molecular docking.
Ammar UM; Abdel-Maksoud MS; Mersal KI; Ali EMH; Yoo KH; Choi HS; Lee JK; Cha SY; Oh CH
Bioorg Med Chem Lett; 2020 Oct; 30(20):127478. PubMed ID: 32781217
[TBL] [Abstract][Full Text] [Related]
4. Discovery of New Imidazo[2,1-
Abdel-Maksoud MS; El-Gamal MI; Lee BS; Gamal El-Din MM; Jeon HR; Kwon D; Ammar UM; Mersal KI; Ali EMH; Lee KT; Yoo KH; Han DK; Lee JK; Kim G; Choi HS; Kwon YJ; Lee KH; Oh CH
J Med Chem; 2021 May; 64(10):6877-6901. PubMed ID: 33999621
[TBL] [Abstract][Full Text] [Related]
5. Anticancer profile of newly synthesized BRAF inhibitors possess 5-(pyrimidin-4-yl)imidazo[2,1-b]thiazole scaffold.
Abdel-Maksoud MS; Ammar UM; Oh CH
Bioorg Med Chem; 2019 May; 27(10):2041-2051. PubMed ID: 30955995
[TBL] [Abstract][Full Text] [Related]
6. Imidazothiazole-based potent inhibitors of V600E-B-RAF kinase with promising anti-melanoma activity: biological and computational studies.
Anbar HS; El-Gamal MI; Tarazi H; Lee BS; Jeon HR; Kwon D; Oh CH
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1712-1726. PubMed ID: 32962435
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of imidazo[2,1-b]thiazole-based anticancer agents in one decade (2011-2020): Current status and future prospects.
Sbenati RM; Semreen MH; Semreen AM; Shehata MK; Alsaghir FM; El-Gamal MI
Bioorg Med Chem; 2021 Jan; 29():115897. PubMed ID: 33316752
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis, biological evaluation, and docking studies of novel (imidazol-5-yl)pyrimidine-based derivatives as dual BRAF
Ali EMH; El-Telbany RFA; Abdel-Maksoud MS; Ammar UM; Mersal KI; Zaraei SO; El-Gamal MI; Choi SI; Lee KT; Kim HK; Lee KH; Oh CH
Eur J Med Chem; 2021 Apr; 215():113277. PubMed ID: 33601311
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, in vitro antiproliferative evaluation, and kinase inhibitory effects of a new series of imidazo[2,1-b]thiazole derivatives.
Abdel-Maksoud MS; Kim MR; El-Gamal MI; Gamal El-Din MM; Tae J; Choi HS; Lee KT; Yoo KH; Oh CH
Eur J Med Chem; 2015 May; 95():453-63. PubMed ID: 25841200
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of 2,3-dihydroimidazo[2,1-b]thiazoles as dual EGFR and IGF1R inhibitors.
Gadekar PK; Urunkar G; Roychowdhury A; Sharma R; Bose J; Khanna S; Damre A; Sarveswari S
Bioorg Chem; 2021 Oct; 115():105151. PubMed ID: 34333424
[TBL] [Abstract][Full Text] [Related]
11. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.
Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI
Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081
[TBL] [Abstract][Full Text] [Related]
12. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf
Wang GM; Wang X; Zhu JM; Guo BB; Yang Z; Xu ZJ; Li B; Wang HY; Meng LH; Zhu WL; Ding J
Acta Pharmacol Sin; 2017 Jul; 38(7):1059-1068. PubMed ID: 28414204
[TBL] [Abstract][Full Text] [Related]
13. Optimization of diarylthiazole B-raf inhibitors: identification of a compound endowed with high oral antitumor activity, mitigated hERG inhibition, and low paradoxical effect.
Pulici M; Traquandi G; Marchionni C; Modugno M; Lupi R; Amboldi N; Casale E; Colombo N; Corti L; Fasolini M; Gasparri F; Pastori W; Scolaro A; Donati D; Felder E; Galvani A; Isacchi A; Pesenti E; Ciomei M
ChemMedChem; 2015 Feb; 10(2):276-95. PubMed ID: 25430902
[TBL] [Abstract][Full Text] [Related]
14. Bisarylureas Based on 1H-Pyrazolo[3,4-d]pyrimidine Scaffold as Novel Pan-RAF Inhibitors with Potent Anti-Proliferative Activities: Structure-Based Design, Synthesis, Biological Evaluation and Molecular Modelling Studies.
Fu Y; Wang Y; Wan S; Li Z; Wang G; Zhang J; Wu X
Molecules; 2017 Mar; 22(4):. PubMed ID: 28353640
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of a new series of highly potent RAF kinase-inhibiting triarylpyrazole derivatives possessing antiproliferative activity against melanoma cells.
Khan MA; El-Gamal MI; Tarazi H; Choi HS; Oh CH
Future Med Chem; 2016 Dec; 8(18):2197-2211. PubMed ID: 27845592
[TBL] [Abstract][Full Text] [Related]
16. Novel imidazo[2,1-b]thiazole-based anticancer agents as potential focal adhesion kinase inhibitors: Synthesis, in silico and in vitro evaluation.
Başoğlu F; Ulusoy-Güzeldemirci N; Akalın-Çiftçi G; Çetinkaya S; Ece A
Chem Biol Drug Des; 2021 Aug; 98(2):270-282. PubMed ID: 34021971
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, biological evaluation, and modeling studies of novel conformationally-restricted analogues of sorafenib as selective kinase-inhibitory antiproliferative agents against hepatocellular carcinoma cells.
Sbenati RM; Zaraei SO; El-Gamal MI; Anbar HS; Tarazi H; Zoghbor MM; Mohamood NA; Khakpour MM; Zaher DM; Omar HA; Alach NN; Shehata MK; El-Gamal R
Eur J Med Chem; 2021 Jan; 210():113081. PubMed ID: 33310290
[TBL] [Abstract][Full Text] [Related]
18. Potent dual EGFR/Her4 tyrosine kinase inhibitors containing novel (1,2-dithiolan-4-yl)acetamides.
Mansour TS; Pallepati RR; Basetti V
Bioorg Med Chem Lett; 2020 Aug; 30(16):127288. PubMed ID: 32631510
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and evaluation of novel 2-(1H-imidazol-2-yl) pyridine Sorafenib derivatives as potential BRAF inhibitors and anti-tumor agents.
Jiao Y; Xin BT; Zhang Y; Wu J; Lu X; Zheng Y; Tang W; Zhou X
Eur J Med Chem; 2015 Jan; 90():170-83. PubMed ID: 25461318
[TBL] [Abstract][Full Text] [Related]
20. Design and synthesis of new potent anticancer benzothiazole amides and ureas featuring pyridylamide moiety and possessing dual B-Raf(V600E) and C-Raf kinase inhibitory activities.
El-Damasy AK; Lee JH; Seo SH; Cho NC; Pae AN; Keum G
Eur J Med Chem; 2016 Jun; 115():201-16. PubMed ID: 27017549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
